FHTX: Foghorn Price/Earnings to Growth Ratio

The PEG ratio demonstrates stability in business valuation, with the indicator currently standing at 0.00. Foghorn Therapeutics (FHTX) is valued for its Gene Traffic Control platform, which creates precision treatments for oncohematology. The company is implementing energy saving and emission filtration in its laboratories, while its developments are shielded from geopolitical risks and trade disputes by their humanitarian status.

Foghorn Therapeutics - FHTX Price/Earnings to Growth Ratio (period 07/04/2022 - 11/12/2026)

Analytical breakdowns for Foghorn Therapeutics (FHTX)

- share price and consensus valuation forecast:

Price Performance Chart foghorntx.com|FHTX - Analyst Consensus Forecast

- market capitalization information:

Market Value Foghorn|FHTX - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Foghorn Therapeutics|FHTX - Company Book Value|Market-to-Book Ratio foghorntx.com|FHTX - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

FHTX - Net Profit|Expected Net Income Foghorn Therapeutics|FHTX - Price to Earnings Ratio|Projected Price to Earnings Ratio foghorntx.com|FHTX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Foghorn|FHTX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Foghorn Therapeutics|FHTX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months foghorntx.com|FHTX - Net earnings per share growth this year|Projected earnings per share increase next year Foghorn Therapeutics

General company analysis:Foghorn Therapeutics, Inc. - FHTX

Mass-produced product of Foghorn Therapeutics, Inc.

To identify fundamental benchmarks in the financial statements of Foghorn Therapeutics (FHTX), it is critical to correlate market valuation with actual earnings expansion. By analyzing the P/E ratio relative to earnings growth, an investor can determine the asset's degree of undervaluation: a value below one signals growth potential, which in the case of Foghorn Therapeutics (FHTX) is supported by the security of the Gene Control platform and strategic partnerships in the field of cancer therapy.

Competitors of Foghorn Therapeutics

TGTX (TG Therapeutics Inc) - Growth-Adjusted Payback Ratio|PEG Multiple ACLX (Arcellx Corp)|Disc Medicine Pharma - Price/Earnings to Growth Ratio|SNDX - Price/Earnings to Growth Ratio|KURA: Price/Earnings to Growth Ratio|ADC Therapeutics SA (ADCT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Vor Biopharma, Inc. (VOR)|Price/Earnings to Growth Ratio Nkarta Inc.|Price to Earnings Adjusted for Growth Rate Coeptis COEP|PEG Multiple ATNM|estrellabio.com - Growth-Adjusted P/E Ratio|PEG Multiple CASI (CASI Pharmaceuticals, Inc.)|MRKR (Marker Therapeutics Inc) - Market Cap to Earnings and Growth Ratio|INAB - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Eterna Therapeutics|GTBP: PEG Multiple|Price to Net Income Growth Ratio Aptose Biosciences APTO|BPTH (Bio-Path Holdings, Inc.) - PEG Multiple|MEIP: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Vincerx Pharma, Inc. (VINC)